Explore

Citizen Health Uses AI to Support Rare Disease Families

Citizen Health Uses AI to Support Rare Disease Families

Citizen Health, co-founded by Nasha Fitter and Farid Vij, is leveraging AI to support families affected by rare diseases. The platform provides an AI advocate for patients, helping them navigate healthcare challenges and connect with relevant clinical trials. Citizen Health collects and organizes patient data, allowing researchers to advance drug development and treatments. The platform has over 8,000 rare disease patients and collaborates with pharmaceutical companies to reduce therapy timelines by 30-50%. The company has raised $44 million since its launch, with backing from notable investors.

AI in Healthcare: Progress in Drug Discovery but Challenges Remain

AI in Healthcare: Progress in Drug Discovery but Challenges Remain

The integration of AI in healthcare, particularly in drug discovery, has shown promising advancements but also significant challenges. AI technologies have been used to design millions of potential compounds for diseases like Huntington's, yet none have received FDA approval. The pharmaceutical industry remains cautious, as AI has not improved clinical success rates despite speeding up preclinical timelines. Additionally, the use of AI chatbots in healthcare poses risks, with patient safety organizations warning against their unregulated use for medical advice.

GSK Reports Positive Results for Ovarian Cancer Treatment, Boosting Future Sales Prospects

GSK Reports Positive Results for Ovarian Cancer Treatment, Boosting Future Sales Prospects

GSK Reports Positive Results for Ovarian Cancer Treatment, Boosting Future Sales Prospects

CorTec Achieves FDA Breakthrough Designation for Stroke Rehabilitation Brain-Computer Interface

CorTec Achieves FDA Breakthrough Designation for Stroke Rehabilitation Brain-Computer Interface

CorTec has received the FDA's 'Breakthrough Device Designation' for its Brain Interchange system, a fully implantable brain-computer interface (BCI) designed to aid motor recovery in stroke patients. This designation is for the use of direct cortical electrical stimulation to treat chronic stroke-related impairments, marking the first BCI globally to receive this recognition specifically for stroke motor rehabilitation. The Brain Interchange system combines neural signal recording with adaptive stimulation in a closed-loop architecture, aiming to restore motor function. Currently, the system is being evaluated in an FDA-approved investigational device exemption study at the University of Washington in Seattle, representing the first clinical investigation of a fully implantable, wireless BCI system for stroke rehabilitation in humans.

Soleno Therapeutics Faces Securities Fraud Class Action Over Misleading Clinical Trial Data

Soleno Therapeutics Faces Securities Fraud Class Action Over Misleading Clinical Trial Data

Soleno Therapeutics Faces Securities Fraud Class Action Over Misleading Clinical Trial Data

CorTec Receives FDA Breakthrough Designation for Brain-Computer Interface in Stroke Rehabilitation

CorTec Receives FDA Breakthrough Designation for Brain-Computer Interface in Stroke Rehabilitation

CorTec has been granted the 'Breakthrough Device Designation' by the US Food and Drug Administration (FDA) for its Brain Interchange system, a fully implantable brain-computer interface (BCI) aimed at aiding motor recovery in stroke patients. This designation is specifically for the use of direct cortical electrical stimulation to treat chronic stroke-related impairments, marking the first BCI globally to receive such recognition for stroke motor rehabilitation. The FDA's Breakthrough Device program is designed to expedite the development and review of technologies that may offer more effective treatment for life-threatening or irreversibly debilitating conditions. CorTec's system combines neural signal recording with adaptive stimulation in a closed-loop architecture, designed to interpret brain signals and deliver therapeutic stimulation to restore motor function. The platform is currently under evaluation in an FDA-approved investigational device exemption study at the University of Washington in Seattl...

FDA Grants Clearance to Miracell's SMART M-CELL System, Paving Way for U.S. Expansion

FDA Grants Clearance to Miracell's SMART M-CELL System, Paving Way for U.S. Expansion

FDA Grants Clearance to Miracell's SMART M-CELL System, Paving Way for U.S. Expansion

Replimune's Skin Cancer Drug Faces Another FDA Rejection Amid Regulatory Scrutiny

Replimune's Skin Cancer Drug Faces Another FDA Rejection Amid Regulatory Scrutiny

Replimune's Skin Cancer Drug Faces Another FDA Rejection Amid Regulatory Scrutiny

Verastem Oncology Reports Positive Two-Year Follow-Up Data on Combination Therapy for Ovarian Cancer

Verastem Oncology Reports Positive Two-Year Follow-Up Data on Combination Therapy for Ovarian Cancer

Verastem Oncology has announced promising two-year median follow-up data from the Phase 2 RAMP 201 clinical trial evaluating the combination therapy of avutometinib capsules and defactinib tablets in patients with recurrent low-grade serous ovarian cancer (LGSOC). The trial demonstrated sustained clinical benefits, with 52% of patients with a KRAS mutation and 30% of patients with KRAS wild-type remaining on therapy for over a year. The combination therapy showed a well-tolerated safety profile, with no new safety signals and a low discontinuation rate due to adverse events. The data was presented at the Society of Gynecologic Oncology 2026 Annual Meeting, reinforcing the therapy's potential as a durable and clinically meaningful option for patients.

GSK Withdraws Application for Leucovorin Amid Autism Treatment Speculation

GSK Withdraws Application for Leucovorin Amid Autism Treatment Speculation

GSK Withdraws Application for Leucovorin Amid Autism Treatment Speculation

Verastem Oncology Presents Two-Year Follow-Up Data on Combination Therapy for Ovarian Cancer

Verastem Oncology Presents Two-Year Follow-Up Data on Combination Therapy for Ovarian Cancer

Verastem Oncology has announced two-year median follow-up data from its Phase 2 RAMP 201 clinical trial, which evaluated the AVMAPKI® FAKZYNJA® combination therapy in patients with recurrent low-grade serous ovarian cancer (LGSOC). The data was presented at the Society of Gynecologic Oncology (SGO) 2026 Annual Meeting. The trial demonstrated sustained clinical benefits, with 52% of patients with a KRAS mutation and 30% of patients with KRAS wild-type remaining on therapy for over a year. The combination therapy showed a well-tolerated safety profile with no new safety signals and a low discontinuation rate due to adverse events. The study highlights the durability of response and suggests that patients can benefit from long-term administration of the therapy.

START Appoints Dr. Salwan Al Mutar to Enhance Dallas-Fort Worth Oncology Research

START Appoints Dr. Salwan Al Mutar to Enhance Dallas-Fort Worth Oncology Research

The START Center for Cancer Research has appointed Dr. Salwan Al Mutar as the Director of Clinical Research at its Dallas-Fort Worth site. Dr. Al Mutar, an expert in gastrointestinal oncology and early-phase clinical trials, will lead clinical research operations and support the growth of early-phase oncology programs in the region. His previous roles include Assistant Professor at the University of Texas Southwestern Medical Center and attending physician at the Harold C. Simmons Comprehensive Cancer Center. START is the world's largest community-based network of clinical trial sites specializing in early-phase oncology trials. The Dallas-Fort Worth region, with approximately 40,000 new cancer cases annually, offers a significant opportunity for clinical research. START's partnership with OneOncology and The Center for Cancer and Blood Disorders enhances its ability to provide innovative therapies to a diverse patient population.